SHAREHOLDER ALERT: Morris Kandinov Investigating ODT, AYTU, EAR, and CORT; Shareholders are Encouraged to Contact the Firm
08 Setembro 2021 - 8:00AM
National law firm Morris Kandinov is investigating the actions of
the officers and board of directors of Odonate Therapeutics, Inc.,
Aytu Biopharma, Inc., Eargo, Inc., and Corcept Therapeutics,
Inc. If you are a current owner of shares of any of
these stocks, contact leo@moka.law or call (619) 708-3993.
Odonate Therapeutics, Inc.
(NASDAQ: ODT) Accused
of Misleading Investors
On August 4, 2021, Judge Marilyn Huff. of the
United States District Court for the Southern District of
California issued an order denying the defendants’ motion to
dismiss in the pending securities class action against Odonate
Therapeutics, Inc., paving the way for litigation to proceed.
Odonate is a pharmaceutical company formerly focused on the
development of therapeutics for the treatment of cancer. According
to the complaint, defendants made false and misleading statements
regarding the company’s sole drug candidate, tesetaxel. On August
24, 2020, the company disclosed disappointing results from the
trial of tesetaxel. On March 22, 2021, the company disclosed that
it was ending development of tesetaxel following feedback from the
U.S. Food and Drug Administration that the drug was unlikely to
receive approval on the basis of its clinical data package, and
that it would be winding down operations. Morris Kandinov is
investigating Odonate regarding possible breaches of fiduciary
duties and other violations of law, including securities claims on
behalf of shareholders. To learn more about this investigation and
your rights, visit: https://moka.law/case-contact-form/.
Representation is contingency based, no out of pocket costs.
Aytu Biopharma, Inc.
(NASDAQ: AYTU)
Shareholder Rights Investigation
Morris Kandinov is investigating Aytu Biopharma,
Inc. regarding corporate governance failures, possible breaches of
fiduciary duties and other violations of law, including securities
claims on behalf of shareholders, related to recent transactions
and/or events at the company. To learn more about this
investigation and your rights,
visit: https://moka.law/case-contact-form/. Representation is
contingency based, no out of pocket costs.
Eargo, Inc.
(NASDAQ: EAR)
Shareholder Rights Investigation
Morris Kandinov is investigating Eargo, Inc.
regarding corporate governance failures, possible breaches of
fiduciary duties and other violations of law, including securities
claims on behalf of shareholders, related to recent transactions
and/or events at the company. To learn more about this
investigation and your rights,
visit: https://moka.law/case-contact-form/. Representation is
contingency based, no out of pocket costs.
Corcept Therapeutics, Inc.
(NASDAQ: CORT) Accused
of Misleading Investors
On August 24, 2021, Judge Lucy Koh of the United
States District Court for the Northern District of California
issued an order denying in part the defendants’ motion to dismiss
in the pending securities class action against Corcept
Therapeutics, Inc., paving the way for litigation to proceed.
Corcept is a pharmaceutical company that develops medications to
treat severe metabolic, oncologic, and psychiatric disorders.
Corcept’s drug Korylm is a cortisol receptor blocker used to
control hyperglycemia. According to allegations, Corcept was
involved in an off-label marketing scheme involving Korlym. Morris
Kandinov is investigating Corcept regarding possible breaches of
fiduciary duties and other violations of law, including securities
claims on behalf of shareholders. To learn more about this
investigation and your rights,
visit: https://moka.law/case-contact-form/. Representation is
contingency based, no out of pocket costs.
Concerned shareholders are encouraged to contact
Leo Kandinov to learn more:
leo@moka.law (619) 708-3993moka.law
Morris Kandinov LLP is a national law firm that
specializes in recovering investment losses and protecting
stockholder rights. We work on contingency (i.e., you do not pay
our fees out-of-pocket), and our attorneys have made substantial
recoveries for investors in jurisdictions across the
country. The firm would be happy to further discuss
these matters, and any legal rights or remedies potentially
available to you, at no charge.
Attorney Advertising. Past results do not
guarantee a similar outcome.
Contact:
Leo Kandinov, Partnerleo@moka.law619-708-3993550
West B Street, 4th FloorSan Diego, CA 92101moka.law
Odonate Therapeutics (NASDAQ:ODT)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Odonate Therapeutics (NASDAQ:ODT)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024